Clive Morris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Clive Morris has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Enrique Rozengurt
Imperial Cancer Research Fund, PO Box 123, Lincoln's Inn Fields, London WC2A 3PX, England
4 shared publicationsFanyi Zeng
Shanghai Institute of Medical Genetics, Shanghai Stem Cell Institute, Shanghai 200025, People's Republic of China
3 shared publicationsGeoffrey Lomax
California Institute for Regenerative Medicine, San Francisco, CA 94107, USA
3 shared publications- Rosario Isasi
Centre of Genomics and Policy, Faculty of Medicine, Department of Human Genetics, McGill University, Montreal, QC H3A 0G1, Canada
3 shared publications - Douglas Sipp
Center for Biosystems Dynamics Research, RIKEN, Japan
2 shared publications Garry J. Smith
Department of Pathology, Carcinogenesis Research Unit, University of New South Wales, Kensington 2033, Australia
2 shared publications
Latest Publications
- 1 April 2014
- Published by Elsevier in Cell Stem Cell
- Vol. 14 (4) , 427-430
Identifiability and Privacy in Pluripotent Stem Cell Research
- 1 April 2014
- Published by Elsevier in Cell Stem Cell
- Vol. 14 (4) , 427-430
Identifiability and Privacy in Pluripotent Stem Cell Research
- 17 May 2012
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 7 (3) , 439-448
Disclosure and Management of Research Findings in Stem Cell Research and Banking: Policy Statement
Prompted by an increased interest of both research participants and the patient advocacy community in obtaining information about research outcomes and on the use of their biological samples; the international community has begun to debate the emergence of an ethical 'duty' to return research results to participants. Furthermore, the use of new technologies (e.g., whole-genome and -exome sequencing) has revealed both genetic data and incidental findings with possible clinical significance. These technologies together with the proliferation of biorepositories, provide a compelling rationale for governments and scientific institutions to adopt prospective policies. Given the scarcity of policies in the context of stem cell research, a discussion on the scientific, ethical and legal implications of disclosing research results for research participants is needed. We present the International Stem Forum Ethics Working Party's Policy Statement and trust that it will stimulate debate and meet the concerns of researchers and research participants alike.
- 17 May 2012
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 7 (3) , 439-448
Disclosure and Management of Research Findings in Stem Cell Research and Banking: Policy Statement
Prompted by an increased interest of both research participants and the patient advocacy community in obtaining information about research outcomes and on the use of their biological samples; the international community has begun to debate the emergence of an ethical 'duty' to return research results to participants. Furthermore, the use of new technologies (e.g., whole-genome and -exome sequencing) has revealed both genetic data and incidental findings with possible clinical significance. These technologies together with the proliferation of biorepositories, provide a compelling rationale for governments and scientific institutions to adopt prospective policies. Given the scarcity of policies in the context of stem cell research, a discussion on the scientific, ethical and legal implications of disclosing research results for research participants is needed. We present the International Stem Forum Ethics Working Party's Policy Statement and trust that it will stimulate debate and meet the concerns of researchers and research participants alike.
- Open Access
- 29 January 2011
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 7 (3) , 482-484
Publishing SNP Genotypes of Human Embryonic Stem Cell Lines: Policy Statement of the International Stem Cell Forum Ethics Working Party
Novel methods and associated tools permitting individual identification in publicly accessible SNP databases have become a debatable issue. There is growing concern that current technical and ethical safeguards to protect the identities of donors could be insufficient. In the context of human embryonic stem cell research, there are no studies focusing on the probability that an hESC line donor could be identified by analyzing published SNP profiles and associated genotypic and phenotypic information. We present the International Stem Cell Forum (ISCF) Ethics Working Party’s Policy Statement on “Publishing SNP Genotypes of Human Embryonic Stem Cell Lines (hESC)”. The Statement prospectively addresses issues surrounding the publication of genotypic data and associated annotations of hESC lines in open access databases. It proposes a balanced approach between the goals of open science and data sharing with the respect for fundamental bioethical principles (autonomy, privacy, beneficence, justice and research merit and integrity).
- 29 January 2011
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 7 (3) , 482-484
Open AccessPublishing SNP Genotypes of Human Embryonic Stem Cell Lines: Policy Statement of the International Stem Cell Forum Ethics Working Party
Novel methods and associated tools permitting individual identification in publicly accessible SNP databases have become a debatable issue. There is growing concern that current technical and ethical safeguards to protect the identities of donors could be insufficient. In the context of human embryonic stem cell research, there are no studies focusing on the probability that an hESC line donor could be identified by analyzing published SNP profiles and associated genotypic and phenotypic information. We present the International Stem Cell Forum (ISCF) Ethics Working Party’s Policy Statement on “Publishing SNP Genotypes of Human Embryonic Stem Cell Lines (hESC)”. The Statement prospectively addresses issues surrounding the publication of genotypic data and associated annotations of hESC lines in open access databases. It proposes a balanced approach between the goals of open science and data sharing with the respect for fundamental bioethical principles (autonomy, privacy, beneficence, justice and research merit and integrity).
- 1 January 1994
- Published by Springer Nature
- p. 147-152
The Regulation of the Use of Genetically Engineered Cereals as Foods
- 1 January 1994
- Published by Springer Nature
- p. 147-152
The Regulation of the Use of Genetically Engineered Cereals as Foods
- 31 May 1992
- Published by Elsevier in Experimental Cell Research
- Vol. 200 (1) , 149-155
Altered levels and protein kinase C-mediated phosphorylation of substrates in normal and transformed mouse lung epithelial cells
- 31 May 1992
- Published by Elsevier in Experimental Cell Research
- Vol. 200 (1) , 149-155
Altered levels and protein kinase C-mediated phosphorylation of substrates in normal and transformed mouse lung epithelial cells
- 1 January 1991
- Published by Taylor & Francis in Experimental Lung Research
- Vol. 17 (2) , 327-340
EGF-Receptor and Extracellular Matrix Changes in Mouse Pulmonary Carcinogenesis
Malignant Balb/c mouse lung cell clones related to alveologenic carcinoma exhibited low levels of epidermal growth factor (EGF) receptor activity compared to nonmalignant cell clones. Immunoprecipitation of cell homogenates and immunohistochemistry on urethane-induced lung tumors suggest that the absence of activity reflects decreased amounts of EGF receptor protein. Low levels of EGF receptor alone cannot cause neoplastic transformation, since a nonneoplastic cell cone, B5D3, exhibited low levels of EGF receptor despite its nontransformed phenotype. The reduced levels of EGF receptor in malignant clones have been mimicked by long-term (12 h) treatment of a nontransformed cell clone with 200 nM phorbol dibutyrate. The detection of mutated ras oncogene in the transformed cell lines, taken together with the EGF receptor findings, suggests that more than one alteration in the signal transduction pathway may be necessary for transformation in alveologenic adenoma and carcinoma cell systems. A further phenotypic feature of transformation, reduced expression of the extracellular matrix proteins fibronectin and laminin, may be mediated at the transcriptional level.
- 1 January 1991
- Published by Taylor & Francis in Experimental Lung Research
- Vol. 17 (2) , 327-340
EGF-Receptor and Extracellular Matrix Changes in Mouse Pulmonary Carcinogenesis
Malignant Balb/c mouse lung cell clones related to alveologenic carcinoma exhibited low levels of epidermal growth factor (EGF) receptor activity compared to nonmalignant cell clones. Immunoprecipitation of cell homogenates and immunohistochemistry on urethane-induced lung tumors suggest that the absence of activity reflects decreased amounts of EGF receptor protein. Low levels of EGF receptor alone cannot cause neoplastic transformation, since a nonneoplastic cell cone, B5D3, exhibited low levels of EGF receptor despite its nontransformed phenotype. The reduced levels of EGF receptor in malignant clones have been mimicked by long-term (12 h) treatment of a nontransformed cell clone with 200 nM phorbol dibutyrate. The detection of mutated ras oncogene in the transformed cell lines, taken together with the EGF receptor findings, suggests that more than one alteration in the signal transduction pathway may be necessary for transformation in alveologenic adenoma and carcinoma cell systems. A further phenotypic feature of transformation, reduced expression of the extracellular matrix proteins fibronectin and laminin, may be mediated at the transcriptional level.
- 1 May 1990
- Published by Wiley in Journal of Cellular Physiology
- Vol. 143 (2) , 232-242
Fibroblast growth factor stimulates protein kinase C in quiescent 3T3 cells without Ca2+ mobilization or inositol phosphate accumulation
To elucidate the transmembrane signalling processes initiated by fibroblast growth factor (FGF), we have studied the effect of recombinant basic FGF (bFGF) on various early events associated with mitogenesis in Swiss 3T3 fibroblasts. bFGF, at mitogenic concentrations, neither induced Ca2+ mobilization from intracellular stores nor increased the accumulation of inositol phosphates. In contrast, bFGF stimulated the phosphorylation of the Mr 80,000 (80K) cellular protein which is a major substrate of protein kinase C. This effect was potentiated by the diacylglycerol kinase inhibitor R59022. Two‐dimensional polyacrylamide gel electrophoresis and phosphopeptide mapping showed that the 80K phosphoproteins generated in response to bFGF, bombesin, and phorbol 12,13‐dibutyrate were indistinguishable. Down‐regulation of protein kinase C prevented bFGF stimulation of 80K phosphorylation. Other protein kinase C‐dependent early events such as transmodulation of the epidermal growth factor receptor, cytoplasmic alkalinization, inhibition of vasopressin induced increase in cytosolic [Ca2+], and enhancement of cAMP accumulation in response to forskolin were also induced by bFGF. Similar results were obtained when bFGF was added to quiescent cultures of tertiary mouse embryo fibroblasts. We conclude that bFGF stimulates protein kinase C through a signal transduction pathway distinct from inositol phospholipid turnover and Ca2+ mobilization.
- 1 May 1990
- Published by Wiley in Journal of Cellular Physiology
- Vol. 143 (2) , 232-242
Fibroblast growth factor stimulates protein kinase C in quiescent 3T3 cells without Ca2+ mobilization or inositol phosphate accumulation
To elucidate the transmembrane signalling processes initiated by fibroblast growth factor (FGF), we have studied the effect of recombinant basic FGF (bFGF) on various early events associated with mitogenesis in Swiss 3T3 fibroblasts. bFGF, at mitogenic concentrations, neither induced Ca2+ mobilization from intracellular stores nor increased the accumulation of inositol phosphates. In contrast, bFGF stimulated the phosphorylation of the Mr 80,000 (80K) cellular protein which is a major substrate of protein kinase C. This effect was potentiated by the diacylglycerol kinase inhibitor R59022. Two‐dimensional polyacrylamide gel electrophoresis and phosphopeptide mapping showed that the 80K phosphoproteins generated in response to bFGF, bombesin, and phorbol 12,13‐dibutyrate were indistinguishable. Down‐regulation of protein kinase C prevented bFGF stimulation of 80K phosphorylation. Other protein kinase C‐dependent early events such as transmodulation of the epidermal growth factor receptor, cytoplasmic alkalinization, inhibition of vasopressin induced increase in cytosolic [Ca2+], and enhancement of cAMP accumulation in response to forskolin were also induced by bFGF. Similar results were obtained when bFGF was added to quiescent cultures of tertiary mouse embryo fibroblasts. We conclude that bFGF stimulates protein kinase C through a signal transduction pathway distinct from inositol phospholipid turnover and Ca2+ mobilization.
- 1 September 1988
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 155 (2) , 561-568
The diacylglycerol kinase inhibitor R 59022 potentiates bombesin stimulation of protein kinase C activity and DNA synthesis in swiss 3T3 cells
- 1 September 1988
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 155 (2) , 561-568
The diacylglycerol kinase inhibitor R 59022 potentiates bombesin stimulation of protein kinase C activity and DNA synthesis in swiss 3T3 cells
- 25 April 1988
- Published by Wiley in FEBS Letters
- Vol. 231 (2) , 311-316
Purification of a phosphoprotein from rat brain closely related to the 80 kDa substrate of protein kinase C identified in Swiss 3T3 fibroblasts
A phosphoprotein expressed in rat brain is closely related to the 80 kDa substrate of protein kinase C present in 3T3 cells. The protein kinase C substrates from both sources migrate identically on two‐dimensional gel electrophoresis and give similar phosphopeptide fragments when digested with protease. Using a series of chromatographic steps, including DEAE‐cellulose chromatography, Sephadex G150 gel filtration and reverse phase fast protein liquid chromatography, this phosphoprotein was purified 3800‐fold from rat brain. The preparation appears homogenous by one‐ and two‐dimensional gel electrophoresis, is an effective substrate of protein kinase C and contains a high proportion of the acidic amino acids glutamate and aspartate, and of alanine.
- 25 April 1988
- Published by Wiley in FEBS Letters
- Vol. 231 (2) , 311-316
Purification of a phosphoprotein from rat brain closely related to the 80 kDa substrate of protein kinase C identified in Swiss 3T3 fibroblasts
A phosphoprotein expressed in rat brain is closely related to the 80 kDa substrate of protein kinase C present in 3T3 cells. The protein kinase C substrates from both sources migrate identically on two‐dimensional gel electrophoresis and give similar phosphopeptide fragments when digested with protease. Using a series of chromatographic steps, including DEAE‐cellulose chromatography, Sephadex G150 gel filtration and reverse phase fast protein liquid chromatography, this phosphoprotein was purified 3800‐fold from rat brain. The preparation appears homogenous by one‐ and two‐dimensional gel electrophoresis, is an effective substrate of protein kinase C and contains a high proportion of the acidic amino acids glutamate and aspartate, and of alanine.
- 1 June 1987
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 145 (3) , 1026-1032
Interferon inhibition of DNA synthesis in Swiss 3T3 cells: Dissociation from protein kinase C activation
- 1 June 1987
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 145 (3) , 1026-1032
Interferon inhibition of DNA synthesis in Swiss 3T3 cells: Dissociation from protein kinase C activation